RxDoctor Payments Data

Jessica Beebe, DO

Family Medicine · Mount Orab, OHNPI 1992368708

Payments from drug & device makers

$996in general payments, 2019–2025

Across 26 payments — averaging $38.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$268
  • GSK$131
  • Idorsia Pharmaceuticals US Inc$100
  • Astellas Pharma US Inc$97
  • Novo Nordisk$91
  • Abbott$79
  • plus $230 from 8 others

What the payments were for

  • Food & beverage$996100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$996 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$1,631
Medicare patients
22
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol52$55,720
OzempicSemaglutide52$48,401
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$44,958
EliquisApixaban36$39,246
MounjaroTirzepatide23$28,453
TrulicityDulaglutide24$24,654
JardianceEmpagliflozin18$22,711
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$17,575
Advair HfaFluticasone Propion/Salmeterol22$16,567
SymbicortBudesonide/Formoterol Fumarate25$11,255
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$10,719
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,787
Atorvastatin Calcium290$2,006
Metformin Hcl138$1,926
Albuterol Sulfate HfaAlbuterol Sulfate61$1,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$268$84,55090 claims
GSKTrelegy Ellipta, Anoro Ellipta$131$55,67655 claims
Lilly USA, LLCMounjaro, Trulicity$47$53,10747 claims
Novo NordiskOzempic$91$48,40152 claims
Boehringer IngelheimJardiance$16$22,71118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Mount Orab

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →